Piramal Pharma Ltd News

Patent wins vs tariff risks: Analysts picks top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

Stocks to Watch today, Feb 16: Ola Electric, Kfin Tech, Inox Green, HUL

Stocks to Watch today, Feb 16: From Ola Electric to Inox Green Energy, here are few stocks that will be on investors' radar

USFDA issues Form 483 with 4 observations for Piramal Pharma's T'gana plant

Piramal Pharma has said the US health regulator has issued Form 483 with four observations after inspecting its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) conducted an inspection of the company's Digwal (Telangana ) based plant from February 9, 2026, to February 13, 2026. At the conclusion of the inspection, the USFDA issued a Form-483, with four observations, Piramal Pharma said in a regulatory filing on Friday. These observations are related to enhancement in procedures and not related to data integrity and indicated to be classified as a VAI (voluntary action indicated), it added. The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines, the drug maker stated. Piramal Pharma remains committed to maintaining the highest standards of compliance and will work closely with the agency to comprehensively address all the observations, it added. As per the USFDA, Form 48

Stocks to Watch today: Bharti Airtel, Hero MotoCorp, TMPV, LIC, MRF

Stocks to Watch today, February 6, 2026: PhysicsWallah, Mazagon Dock, JK Paper, Sai Life, SKF India, UltraTech Cement, and Federal Bank are among the top stocks to remain in focus today

Piramal Pharma flags early recovery signs in CDMO demand as Q3 loss widens

The company attributed the weaker performance largely to continued inventory destocking in one of its large on-patent commercial products, affecting its CDMO business

Piramal Pharma shares gain 4% on Q3 results; check key highlights inside

Following the results announcement, the company's share price rose 3.78 per cent to log an intraday high of ₹159.79 per share

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Stocks to watch, Dec 12: Tata Power, Astra Microwave, NBCC, Vedanta, Honasa

Stocks to watch today, December 12: Piramal Pharma, Kansai Nerolac and Oswal Pumps are other top stocks to track today.